Similar articles

• Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials.

  Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Umemura Y, et al. J Thromb Haemost. 2016 Mar;14(3):518-30. doi: 10.1111/jth.13230. Epub 2016 Feb 1. J Thromb Haemost. 2016. PMID: 26670422 Review.
• Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: comment.

  Wada H, Matsumoto T, Aota T, Imai H, Suzuki K, Katayama N. Wada H, et al. J Thromb Haemost. 2016 Nov;14(11):2308-2309. doi: 10.1111/jth.13394. Epub 2016 Sep 17. J Thromb Haemost. 2016. PMID: 27331770 No abstract available.
• A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis.

  Freeman BD, Zehnbauer BA, Buchman TG. Freeman BD, et al. Shock. 2003 Jul;20(1):5-9. doi: 10.1097/01.shk.0000068327.26733.10. Shock. 2003. PMID: 12813361
• The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.

  Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, Hébert P, Cook DJ, Fergusson DA; Canadian Critical Care Trials Group. Zarychanski R, et al. Crit Care Med. 2015 Mar;43(3):511-8. doi: 10.1097/CCM.0000000000000763. Crit Care Med. 2015. PMID: 25493972 Review.
• Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.

  Raskob GE, Hirsh J. Raskob GE, et al. Chest. 2003 Dec;124(6 Suppl):379S-385S. doi: 10.1378/chest.124.6_suppl.379s. Chest. 2003. PMID: 14668421 Review.